Pharming Group N.V. (PHAR)
NASDAQ: PHAR · Real-Time Price · USD
11.81
+0.57 (5.10%)
Jun 3, 2025, 4:00 PM - Market closed
Pharming Group Revenue
Pharming Group had revenue of $79.09M in the quarter ending March 31, 2025, with 42.29% growth. This brings the company's revenue in the last twelve months to $320.71M, up 24.13% year-over-year. In the year 2024, Pharming Group had annual revenue of $297.20M with 21.15% growth.
Revenue (ttm)
$320.71M
Revenue Growth
+24.13%
P/S Ratio
2.52
Revenue / Employee
$793,832
Employees
404
Market Cap
808.52M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 297.20M | 51.88M | 21.15% |
Dec 31, 2023 | 245.32M | 39.69M | 19.30% |
Dec 31, 2022 | 205.62M | 6.75M | 3.39% |
Dec 31, 2021 | 198.87M | -13.30M | -6.27% |
Dec 31, 2020 | 212.17M | 22.79M | 12.03% |
Jan 1, 2020 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
PHAR News
- 6 days ago - Pharming Group to participate in June investor conferences - GlobeNewsWire
- 25 days ago - Pharming Group N.V. (PHAR) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 26 days ago - Pharming Group reports first quarter 2025 financial results and provides business update - GlobeNewsWire
- 4 weeks ago - Pharming Group announces the 2025 Annual General Meeting of Shareholders and the nomination of a new Non-Executive Director - GlobeNewsWire
- 5 weeks ago - Pharming Group to report first quarter 2025 financial results on May 8 - GlobeNewsWire
- 5 weeks ago - Pharming receives positive recommendation from NICE for Joenja®▼(leniolisib) as a treatment for APDS - GlobeNewsWire
- 2 months ago - Pharming Group announces the filing of its 2024 Annual Report and Form 20-F - GlobeNewsWire
- 2 months ago - Pharming Group to participate in April investor conferences - GlobeNewsWire